Site notifications

Sub menu

 

 

MADOPAR RAPID 62.5 levodopa 50 mg and benserazide 12.5 mg dispersible tablet bottle, Roche Products Pty Ltd, CON-1265

Product name
MADOPAR RAPID 62.5 levodopa 50 mg and benserazide 12.5 mg dispersible tablet bottle
Sponsor name
Roche Products Pty Ltd
ARTG details
Consent start
Consent no.
CON-1265
Duration
The consent is effective from 26 August 2024 until 31 August 2025.
Standard
Paragraph 6(1)(a) of Therapeutic Goods Order No. 95 - Child-resistant packaging requirements for medicines 2017 (TGO 95)
Non-compliance with standard
The products are not contained within child-resistant packaging.
Conditions imposed
The sponsor will continue to monitor for any incidents where a child accesses the medicine inappropriately and report all such incidents to the Therapeutic Goods Administration.
Import, Supply, &/or Export
import and supply
Therapeutic product type
Prescription medicines